What did @popethecoach actually say?
At week 19 of TRT, @popethecoach reported starting with a baseline testosterone of 217 ng/dL, titrating up to 160mg per week split into two 80mg injections, reaching a level of 974 ng/dL. He then increased to 200mg per week because, as he put it, "something was missing" specifically "the energy aspect." He also mentioned managing acne with a powdered supplement from his hormone clinic.
This is a personal progress update, not a medical recommendation. He does not tell viewers to take 200mg, does not cite a doctor's guidance on camera, and does not claim this protocol works for everyone. That matters when we evaluate what he actually put out there versus what viewers might take away from it.
Does the science back this up?
Partially. The general framework he describes, titrating dose based on labs and symptoms, is consistent with how TRT is actually managed. But the specific numbers deserve scrutiny.
A baseline of 217 ng/dL is genuinely low. The Endocrine Society defines hypogonadism as total testosterone below 300 ng/dL on two morning measurements, so his starting point would qualify in most clinical guidelines (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism). Reaching 974 ng/dL on 160mg per week falls within the upper-normal physiological range, which most guidelines consider acceptable for TRT. Pushing to 200mg per week to chase more energy is where the science gets murkier. Research does not clearly establish that supraphysiological levels improve energy or well-being over high-normal levels. A randomized trial by Snyder et al. (2016, NEJM) found modest energy benefits at normal testosterone restoration, but the dose-response curve beyond that is not well-supported in controlled data.
What did they get wrong (or right)?
He got the split-dosing logic right. Injecting twice weekly, rather than once, smooths out the peak-and-trough testosterone fluctuation. This is genuinely good practice and supported by pharmacokinetic data on testosterone cypionate and enanthate (Behre et al., 1999, Clinical Endocrinology).
Where he is on shakier ground is framing "energy" as a justification for increasing beyond a level where he already felt good. At 974 ng/dL he was already in the upper-normal range. The idea that more testosterone means more energy is a common belief in TRT communities, but the evidence for this above normal physiological levels is weak. More importantly, he does not mention that 200mg per week can meaningfully elevate hematocrit, suppress HDL cholesterol, and increase cardiovascular risk over time. The acne he mentions is a real signal that androgenic activity is high. Those side effects deserved at least a mention alongside the energy wins.
The powdered supplement for acne is listed without any product name or ingredient breakdown, so it cannot be evaluated here. That is not a red flag on its own, but viewers should not assume clinic-provided supplements are clinically validated for acne management in TRT contexts.
What should you actually know?
A few things that this video does not cover but should be on your radar if you are on TRT or considering it.
- Testosterone above 1000 ng/dL is associated with increased erythrocytosis risk. Hematocrit should be monitored regularly, especially when doses increase (Coviello et al., 2008, Journal of Clinical Endocrinology and Metabolism).
- The 550 ng/dL threshold in the caption as a prompt to comment about TRT has no strong clinical basis. Symptoms matter as much as numbers. A 2020 review in Andrology by Mulhall et al. found that symptom assessment tools like the ADAM questionnaire should accompany lab values in treatment decisions.
- "Energy" is one of the least specific TRT outcomes in research. Sleep quality, thyroid function, iron levels, and cortisol are common culprits for fatigue in men who have normal or even high testosterone levels.
- Dose increases should happen with, not between, clinical lab monitoring. If you are increasing based on how you feel without updated bloodwork, you are flying partially blind.